Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.68), $0.04 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.